Tag: Lambert-Eaton Myasthenic Syndrome (LEMS)
FDA Approves Firdapse® (Amifampridine) For The Treatment Of Lambert-Eaton Myasthenic Syndrome (LEMS)

CORAL GABLES, Fla., Nov. 29, 2018 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Firdapse® (amifampridine) 10 mg tablets for the treatment […]